Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-742X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings ; volume:48 ; number:4 ; day:20 ; month:8 ; year:2019 ; pages:653-660 ; date:11.2019
Journal of thrombosis and thrombolysis ; 48, Heft 4 (20.8.2019), 653-660, 11.2019
- Urheber
-
Ikeda, Takanori
Ogawa, Satoshi
Kitazono, Takanari
Nakagawara, Jyoji
Minematsu, Kazuo
Miyamoto, Susumu
Murakawa, Yuji
Iwashiro, Sanghun
Kidani, Yoko
Okayama, Yutaka
Sunaya, Toshiyuki
Sato, Shoichiro
Yamanaka, Satoshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11239-019-01934-6
- URN
-
urn:nbn:de:101:1-2020021501372013308464
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ikeda, Takanori
- Ogawa, Satoshi
- Kitazono, Takanari
- Nakagawara, Jyoji
- Minematsu, Kazuo
- Miyamoto, Susumu
- Murakawa, Yuji
- Iwashiro, Sanghun
- Kidani, Yoko
- Okayama, Yutaka
- Sunaya, Toshiyuki
- Sato, Shoichiro
- Yamanaka, Satoshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Psychiatric symptoms in patients with non-valvular atrial fibrillation
Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Evaluation of Apixaban standard dosing in underweight patients with non-valvular atrial fibrillation: a retrospective cohort study
Initial rivaroxaban dosing in patients with atrial fibrillation
Correction: Psychiatric symptoms in patients with non-valvular atrial fibrillation
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis